TY  - GEN
AU  - Bowler,S
AU  - Siriwardhana,C
AU  - Mitchell,B I
AU  - D'Antoni,M L
AU  - Ogata-Arakaki,D
AU  - Souza,S
AU  - Yee,R
AU  - Gangcuangco,L M A
AU  - Chow,D C
AU  - Ndhlovu,L C
AU  - Shikuma,C
TI  - Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy
SN  - 2578-7470
PY  - 2020///0528
KW  - Anti-HIV Agents
KW  - therapeutic use
KW  - Biomarkers
KW  - blood
KW  - CCR5 Receptor Antagonists
KW  - Cohort Studies
KW  - Female
KW  - HIV Infections
KW  - Humans
KW  - Imidazoles
KW  - Inflammation
KW  - Macrophages
KW  - immunology
KW  - Male
KW  - Middle Aged
KW  - Monocytes
KW  - Receptors, CCR2
KW  - antagonists & inhibitors
KW  - Sulfoxides
N1  - Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1080/25787489.2020.1719319
ER  -